We innovate to reduce health disparities around the world.

Our mission

Global Health Labs (GH Labs) is a nonprofit organization. We build tools and technologies to address unmet needs in primary healthcare centers and last-mile service delivery in low- and middle-income countries (LMICs) around the world.

Why we do what we do

We innovate for impact, delivering healthcare solutions to the communities that need them most and supporting the strategic priorities of the Bill & Melinda Gates Foundation.

How we approach our work

Together, our multidisciplinary teams of scientists, researchers, global health experts and operations specialists develop stepping stones and comprehensive pathways from real world problems to real world solutions. We move and adapt quickly; embrace new challenges and perspectives; and share our tools, data, and findings as openly as possible.

In response to the COVID-19 pandemic, GH Labs incubated and developed a new COVID-19 antigen test. Previously, GH Labs scientists developed a novel ultrasound technology suited to low-resource environments, and a vaccine cold chain container, among others.

Our areas of focus

GH Labs develops innovative solutions to address critical technology gaps in low-resource environments with a focus on three primary areas serving Low- and Middle-Income Countries (LMICs):

  1. Diagnostics (Dx)
  2. Tools and Technologies for Maternal, Newborn and Child Health (MNCH)
  3. Primary Healthcare Center (PHC) Hardware and Equipment

Our Work

DIAGNOSTICS & IMAGING

COVID LFA Platform

Learn MoreOrange Plus Sign

NEW TECHNOLOGIES

IN-SITU Oxygen Filling and Storage System

Learn MoreOrange Plus Sign

SENSORS & WEARABLES

Machine Learning for HPV and Cervical Cancer

Learn MoreOrange Plus Sign

Our Board and Leadership Team

  • Niranjan

    Bose

    Board Member

    Niranjan

    Bose

    Board Member

    Niranjan Bose serves as member of the Board of Directors at GH Labs. Currently, he is Managing Director for Health & Life Sciences Strategy at Gates Ventures LLC, where he also serves as Science Advisor to Bill Gates.

    Prior to joining Gates Ventures in 2014, he was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation. During his tenure there, he was responsible for managing a portfolio of vaccine investments focused on pediatric diarrheal and respiratory diseases. This work included leading the Foundation’s cholera and rotavirus vaccine strategies.

    Before that, Niranjan worked for the management consulting firm Strategic Decisions Group (and SDG Life Sciences), where his engagements with pharma and biotech clients drove strategy development, deal structuring, and portfolio management.

    Niranjan holds a Ph.D. in Biochemistry from Dartmouth College, an M.S. in Biological Sciences and a B.S. in Pharmaceutical Sciences from the Birla Institute of Technology and Science, in Pilani, India. He also holds a Business Bridge Diploma from the Tuck School of Business at Dartmouth.

  • Elisa

    Keller

    Board Member

    Elisa

    Keller

    Board Member

    Elisa Mandell Keller serves as member of the Board of Directors at GH Labs. Currently, she is the principal of EMK Strategic Consulting, a firm that provides strategic guidance and analysis to for-profit and nonprofit organizations.

    Previously, Elisa worked at the Bill & Melinda Gates Foundation, most recently as Director and Chief of Staff to the Foundation’s Chief Strategy Officer and President of Global Policy & Advocacy. She also served as Deputy Director for Strategy, Planning and Management for the Agricultural Development team and as was Chief of Staff to the president of the Gates Foundation’s Global Development Program.

    Before she joined the Foundation, Elisa was a consultant with PATH (Program for Appropriate Technology in Health), helping create a social equity fund to invest in health technologies relevant to the developing world. She has also worked as a high school teacher in the rural village of Oshikuku, Namibia, as well as for New York City Schools’ Chancellor Joel Klein. Elisa began her career at McKinsey & Company in Seattle, working on healthcare and biotechnology, retail, and U.S. and international education.

    Elisa holds a B.S. in Education and Social Policy with a focus on organizational development from Northwestern University.

  • Ankur

    Vora

    Board Member

    Ankur

    Vora

    Board Member

    Ankur Vora serves as member of the Board of Directors at GH Labs. Currently, he is Chief Strategy Officer of the Bill & Melinda Gates Foundation, where he serves as principal advisor to the co-chairs, chief executive officer, and Executive Leadership Team on the foundation’s overall strategic opportunities, risks, and tradeoffs. He leads the Strategy Office, which is responsible for enabling the highest and best use of the Foundation’s resources – co-chair time, reputation, people, and dollars – to accelerate the Foundation’s impact.

    Prior to joining the Foundation, Ankur was the director of programs at the Children’s Investment Fund Foundation (CIFF) in London, where he oversaw a cross-cutting portfolio of programs focused on health, nutrition, education, and climate change across Africa and South Asia.

    He has also served as principal at the Boston Consulting Group (BCG), where he focused on healthcare, financial services, and social impact projects. Before that, Ankur was a lecturer of Economics at the University of Chicago. He also worked briefly at Goldman Sachs, the Industrial Development Bank of India, and the Bhabha Atomic Research Center in India.

    Additionally, he serves on the Board of Directors at Innovations for Poverty Action.

    Ankur holds a Ph.D. in Economics from the University of Chicago, and an M.S. in Economics and B.S. in Computer Science from the Birla Institute of Technology and Science, in Pilani, India.

  • Shashi

    Buluswar

    Chief Executive Officer

    Shashi

    Buluswar

    Chief Executive Officer

    As Chief Executive Officer of GH Labs, Shashi Buluswar leads the organization and its multidisciplinary team of scientists, researchers, global health experts, project managers and operations specialists in developing breakthrough innovations to address critical technology gaps in low-resource environments, with a focus on diagnostics, tools for maternal, newborn, and child health, and primary healthcare centers.

    Shashi has spent more than 25 years working as a global development expert, scientist, and business strategist, to drive innovative solutions and breakthrough technologies to combat global poverty, and address disparities in health, water security, environmental protection, and energy access.

    Prior to joining GH Labs, he founded the Institute for Transformative Technologies (ITT), where he also served as CEO. He was the chief architect of the largest electrification and natural sanitation initiatives in the world, in India. He is also the principal author of the “50 Breakthroughs” study, which examines technologies across nine categories—including global health, agricultural development, and digital inclusion—needed to achieve the Sustainable Development Goals (SDGs). The study was called the “first-of-its-kind blueprint for sustainable development” by the Lawrence Berkeley National Laboratory and has been recognized by the UN Commission on Science and Technology for Development as a technology roadmap for the SDGs.

    Prior to ITT, Shashi was a partner at the consulting firm Dalberg Global Development Advisors, serving multilaterals, international NGOs, foundations, governments, and social entrepreneurs. He was also Associate Partner at McKinsey & Company, and a Computer Science lecturer at Northwestern University. Today, he is Business and Social Impact lecturer at the University of California, Berkeley’s Haas School of Business.

    Shashi holds a Ph.D. in Artificial Intelligence from the University of Massachusetts, an MBA from Northwestern University’s Kellogg School of Management, and a B.A. from Goshen College.

     

  • Sharon

    Bergquist

    INTERIM VP, STRATEGY & PLANNING

    Sharon

    Bergquist

    INTERIM VP, STRATEGY & PLANNING

    As Interim Vice President of Strategy and Planning at GH Labs, Sharon Bergquist is responsible for maintaining strong alignment between GH Labs and the Bill & Melinda Gates Foundation, including strategic alignment of project portfolios in tools and technologies for Primary Healthcare Centers (PHC), Maternal Newborn Child Health (MNCH), and Diagnostics (Dx), ensuring the development of high-quality project plans with clear articulation of critical decision points for implementation. She also oversees GH Labs steering committees and helps shape internal processes to ensure robust and effective collaboration with external partners.

    Previously, Sharon was a Director at Gates Ventures’ Health & Life Sciences team, where she managed a portfolio that includes the Seattle Flu Study/SCAN and Alzheimer’s Disease therapeutics investments. She also managed the Bill & Melinda Gates Foundation’s and GH Labs’ relationships on MNCH, Discovery and Translational Sciences, Vaccine Development and Surveillance, and Pneumonia, focusing largely on strategy reviews, learning agendas and research intersections.

    Prior to working at Gates Ventures, Sharon worked at the Bill & Melinda Gates Foundation, where she was most recently on Melinda Gates’ strategy team, after working on the MNCH Discovery and Tools team leading the neurodevelopment initiative.

    Sharon received her Ph.D. in Neuroscience from the University of California, San Francisco, and her B.S. in Biology from the University of California, San Diego.

  • Jim

    Bromley

    INTERIM VP, FINANCE & OPERATIONS

    Jim

    Bromley

    INTERIM VP, FINANCE & OPERATIONS

    As Interim Vice President of Finance and Operations at GH Labs, Jim Bromley is responsible for Finance, IT, Facilities, Safety, and Project Management and Quality.

    Prior to joining GH Labs, Jim served as Chief Financial Officer at the Bill & Melinda Gates Foundation, where previously, he served Managing Director, Financial Planning and Global Programs Operations.

    He has also served as Interim Chief Financial Officer of Forterra NW, and Executive Vice President and President of Nordstrom Inc., Catalog and Internet Divisions.

    Jim holds a B.A. in Economics from Middlebury College.

     

     

  • Davina

    Inslee

    VP, Legal

    Davina

    Inslee

    VP, Legal

    As Vice President of Legal at GH Labs, Davina Inslee oversees all legal matters, including contracts, technology transfer, tax planning, regulatory, corporate governance, and compliance.

    Prior to joining GH Labs, she was Counsel at the firm Davis Wright Tremaine. Her practice concentrated on the technology industry, including product development and commercialization, intellectual property licensing, compliance, and distribution.

    Before that, Davina was a Chief Counsel at Vulcan Inc. and Intellectual Ventures, where she supported development for diagnostics, machine learning, clean energy, and other transformative technologies with an emphasis in biotechnology. Her work led to product development for affordable and accessible technologies that solve the biggest problems in global health, such as malaria diagnostics, portable, smart ultrasound, HPV image recognition, medical cold-chain equipment, computational disease modeling, and rapid diagnostics.

    Davina holds a J.D. from Indiana University and a B.S. in Biological Sciences from Purdue University.

  • Rob

    Jenison

    VP, Research & Product Development

    Rob

    Jenison

    VP, Research & Product Development

    As Vice President of Research and Product Development at GH Labs, Rob Jenison oversees the translation of inventive technologies into products through commercial partnerships, to serve the needs of people in LMICs.

    Prior to joining GH Labs, Rob served as Vice President of Product Development and Commercialization Strategy at Global Good. Previously, he served as CTO/SVP R&D at Great Basin Scientific (now Vela Diagnostics) where he led the creation of a molecular diagnostic platform that resulted in six FDA-approved products. Before that, Rob led the development of a high-throughput genotyping platform at Thermo Biostar in collaboration with the Nichols Institute, Quest Diagnostics. Rob also developed RNA-based diagnostic and therapeutic agents at NeXstar Pharmaceuticals and Ionis Pharmaceuticals.

    Rob holds a B.S. in Chemistry/Biochemistry from the University of California, San Diego.

  • Andrea

    Lee

    VP, Human Resources

    Andrea

    Lee

    VP, Human Resources

    As Vice President of Human Resources at GH Labs, Andrea Lee is responsible for driving people leadership, management excellence, and organization effectiveness including values, culture and all people operations and functions.

    Prior to joining GH Labs, Andrea worked at the Bill & Melinda Gates Foundation, where she most recently led Talent Development, partnering collaboratively to assess, design, and deliver enterprise-wide talent development resources and programs in service of the Foundation’s impact, including onboarding, performance management, and manager and team effectiveness. Prior to that, Andrea applied progressive HR best practices in diverse settings and industries, and in cultures of servant-leadership, innovation, and people development like those at Starbucks and Cranium.

    Andrea holds an MBA from the Stephen M. Ross School of Business at the University of Michigan and a B.A. in Education from the University of Calgary.

  • Daniel

    Lieberman

    Senior Director, Engineering & Software

    Daniel

    Lieberman

    Senior Director, Engineering & Software

    As Senior Director of Engineering and Software at GH Labs, Daniel Lieberman oversees the development of technologies to bridge gaps in primary healthcare.

    Before he joined GH Labs, Daniel managed a team at Exponent, an engineering consulting firm engaging in failure analysis and product design. He has also held part-time faculty positions at the University of Southern California and at École des Métiers de l’Aérospatiale de Montréal. An engineer by training, Daniel has more than 20 years of experience investigating thermo-fluid systems in a number of areas including cryogenics, respiratory systems, chemically reacting flows, and propulsion devices.

    Daniel holds a Ph.D. and M.S. in Aeronautics from the California Institute of Technology and a B.Eng. in engineering from McGill University.

  • Bernhard

    Weigl

    Senior Director, Diagnostics Research & Development

    Bernhard

    Weigl

    Senior Director, Diagnostics Research & Development

    As Senior Director of Diagnostics Research and Development at GH Labs, Bernhard H. Weigl leads work to develop the next generation of highly sensitive diagnostic assays for diseases of relevance in LMICs, including TB, cervical cancer, malaria, and more recently, COVID-19. He also oversees the development of global health diagnostic technology R&D, including ultra-sensitive strip-based immunoassays, molecular assays in cartridge and digital formats, novel assay formats, and other biotechnology research.

    Previously, Bernhard led the PATH Diagnostics Group, where he oversaw global health diagnostics programs funded by a variety of sources such as NIAID and NIBIB, the Grand Challenges program of the Bill & Melinda Gates Foundation, USAID, and the PATH Health Innovation Portfolio. He also served as Portfolio Leader for Non-Communicable Disease Diagnostics and as Director of the National Institutes of Health-funded Center for Point-of-Care Diagnostics for Global Health. Prior to that, he was a scientific cofounder at the University of Washington and at Micronics, Inc., where he led teams that developed both instrument-based and stand-alone microfluidic medical diagnostic disposables (including the ABORhCard®, the first FDA-approved instrument-free microfluidic test). Bernhard is also an Affiliate Professor at the University of Washington, Department of Bioengineering.

    Bernhard holds a Ph.D. and M.Sc from Karl-Franzens-University Graz. He completed post-doctoral studies at the University of Southampton and the University of Washington.

CloseOrange Exit Button